Buy & Sell Nuscale Power Corporation (SMR) – Nuscale Power Corporation Price Today
Aura AI Summary
Key Stats
- $3.72BMarket Cap
- UtilitiesSector
- -26.41%3M Drawdown
- $2.83BEnterprise Value
- -Dividend Yield
- 52% Buy | 48% SellTrading Activity
- 11 daysTypical Hold Time
Nuscale Power Corporation (SMR) is currently valued at a market capitalization of $3.72B, with an enterprise value of $2.83B. Over the past 52 weeks, Nuscale Power Corporation has traded between a low of $9.16 and a high of $53.43, highlighting its annual price range. Over the past three months, Nuscale Power Corporation has recorded a drawdown of -26.41%, reflecting recent price volatility. On average, investors hold Nuscale Power Corporation for approximately 11 days, indicating typical investor behavior on the platform.
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Most Recent News
Gilead and Merck halt lung cancer trial but report positive HIV drug Phase 3 results.
Gilead Sciences and Merck have stopped their Phase 3 trial combining Trodelvy and Keytruda for metastatic non-small cell lung cancer after it failed to show statistically significant benefits. However, they announced positive Phase 3 results for a ne...

American Airlines signs largest sustainable aviation fuel deal with Google, boosting stock.
American Airlines has signed the largest sustainable aviation fuel (SAF) certificate agreement with Google, securing 35 million gallons of SAF over three years to reduce nearly 300,000 metric tons of CO₂ emissions. This deal supports American Airline...

Over 29 pharma firms advance 35+ Treg cell therapies, promising new treatments for autoimmune and transplant diseases.
The Treg cell-based therapies pipeline is robust with more than 29 pharmaceutical companies developing over 35 therapies targeting autoimmune diseases, graft-versus-host disease, and transplant rejection. Key players like Orca Bio, Cellenkos, and Que...
